Drugs for Ehlers-Danlos Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 47)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Irbesartan |
Approved, Investigational |
Phase 3 |
|
138402-11-6 |
3749 |
Synonyms:
2-Butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-N-Butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one
Aprovel
Aprovel®|Avapro®|Karvea®|SR 47436
Avalide
Avapro
BMS 186295
BMS-186295
|
IFIRMASTA
Irbesarran
IRBESARTAN
Irbesartan [Usan:Inn]
Karvea
Lrbesartan
SABERVEL
SR-47436
|
|
2 |
|
Angiotensin II |
Approved, Investigational |
Phase 3 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
3 |
|
Celiprolol |
Approved, Investigational |
Phase 3 |
|
56980-93-9 |
2663 |
Synonyms:
CELECTOL
Celiprolol
Celiprololum
REV 5320
|
RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
SELECTOL
ST1396
ST-1396
|
|
4 |
|
Lidocaine |
Approved, Vet_approved |
Phase 3 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
5 |
|
Angiotensinogen |
|
Phase 3 |
|
|
16133225 |
Synonyms:
Hypertensinogen
Proangiotensin
Renin substrate
Renin substrate tetradecapeptide
|
Renin-substrate
Serpin a8
SERPINA8
Tetradecapeptide, renin substrate
|
|
6 |
|
Angiotensin Receptor Antagonists |
|
Phase 3 |
|
|
|
7 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 3 |
|
|
|
8 |
|
Giapreza |
|
Phase 3 |
|
|
|
9 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
10 |
|
Adrenergic beta-Antagonists |
|
Phase 3 |
|
|
|
11 |
|
Adrenergic beta-1 Receptor Antagonists |
|
Phase 3 |
|
|
|
12 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
13 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
14 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
15 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
16 |
|
Sympathomimetics |
|
Phase 3 |
|
|
|
17 |
|
Anti-Arrhythmia Agents |
|
Phase 3 |
|
|
|
18 |
|
Sodium Channel Blockers |
|
Phase 3 |
|
|
|
19 |
|
Anesthetics, Local |
|
Phase 3 |
|
|
|
20 |
|
Anesthetics |
|
Phase 3 |
|
|
|
21 |
|
Diuretics, Potassium Sparing |
|
Phase 3 |
|
|
|
22 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
23 |
|
Droxidopa |
Approved, Investigational |
Phase 1, Phase 2 |
|
23651-95-8 |
443940 92974 |
Synonyms:
(-)-(2S,3R)-2-AMINO-3-HYDROXY-3-(3,4-DIHYDROXYPHENYL)PROPANOIC ACID
(2R,3S)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate
(2S,3R)-3,4-DIHYDROXY-PHENYLSERINE
3,4 Dihydroxyphenylserine
3,4 Threo dops
3,4-Dihydroxyphenylserine
3,4-Threo-dops
DL Threo 3,4 dihydroxyphenylserine
DL-Threo-3,4-dihydroxyphenylserine
Dops
Droxidopa
Droxidopa, (DL-tyr)-isomer
Droxydopa
Erythro 3,4 dihydroxyphenylserine
|
Erythro-3,4-dihydroxyphenylserine
L-Dihydroxyphenylserine
L-DOPS
L-DOPS|Northera®|SM-5688
L-Threo-3,4-dihydroxyphenylserine
L-threo-dihydroxyphenylserine
L-THREODOPS
Northera
SM 5688
SM-5688
Threo dops
THREO-DOPASERINE
Threo-dops
|
|
24 |
|
Oxytocin |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
50-56-6 |
439302 53477758 |
Synonyms:
(2S)-2-[({1-[(4R,7S,10S,13S,16S,19R)-19-amino-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-7-[(C-hydroxycarbonimidoyl)methyl]-16-[(4-hydroxyphenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carbonyl]pyrrolidin-2-yl}(hydroxy)methylidene)amino]-N-[(C-hydroxycarbonimidoyl)methyl]-4-methylpentanimidate
(Arg8)-vasopressin
(Arg8)-vasotocin
[<sup>3</sup>H]oxytocin
alpha-Hypophamine
Argipressin
Argpressin acetate
Biotinyl-(arg8)-vasopressin
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
Disulfide bridge cys1-cys6
Gly-leu-pro-c
Ocytocin
|
ORASTHIN
Oxitocina
OXT
OXYTOCIN
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
PITOCIN
SID29217903
SID50111741
SYNTOCINON
SYNTOMETRINE
SYT670
TTA-121
|
|
25 |
|
Antiparkinson Agents |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Acetylcholine |
Approved, Investigational |
|
|
51-84-3 |
187 |
Synonyms:
[2-(ACETYLOXY)ETHYL]TRIMETHYLAZANIUM
2-(Acetyloxy)-N,N,N-trimethylethanaminium
2-ACETOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AZANIUM
Acetilcolina cusi
Acetyl choline ion
Acetylcholine
Acetylcholine bromide
Acetylcholine cation
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
ACETYLCHOLINE, ACH
Acetylcholinium: acetyl-choline
|
ACh
ACh|E1001|O-acetylcholine
Alcon brand OF acetylcholine chloride
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
E1001
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
27 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
28 |
|
Mecasermin |
Approved, Investigational |
|
|
68562-41-4 |
|
Synonyms:
CEP-151
Human somatomedin C
IGF1
IGF-1
INCRELEX
INSULIN-LIKE GROWTH FACTOR 1
INSULIN-LIKE GROWTH FACTOR I
|
MECASERMIN
MECASERMIN RECOMBINANT
MECASERMIN RINFABATE
Mecasermina
MECHANO GROWTH FACTOR
MYOTROPHIN
SOMATOMEDIN-C
|
|
29 |
|
Thrombin |
Approved, Investigational |
|
|
|
|
Synonyms:
coagulation factor II
THROMBIN
Thrombin bovine
|
Thrombin, Topical (Bovine)
THROMBOSTAT
|
|
30 |
|
Bupivacaine |
Approved, Investigational |
|
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
(+-)-Bupivacaine
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Abbott brand OF bupivacaine hydrochloride
ANEKAIN
Anhydrous, bupivacaine
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bloqueina
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
Bucaine
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
BUPIVACAINE
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
|
Carbonate, bupivacaine
Carbostesin
CBupivacaine
Chirocaine
DepoBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
DL-Bupivacaine|Exparel®|Marcain®|Posimir®|Sensorcaine®|W-7|Xaracoll®
Dolanaest
DUR-843
Exparel
Hydrochloride, bupivacaine
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
LAC-43
LIQ865
LIQ-865
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
Pisa brand OF bupivacaine hydrochloride
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SKY-0402
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
|
|
31 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
|
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
32 |
|
Riboflavin |
Approved, Investigational, Nutraceutical, Vet_approved |
|
|
83-88-5 |
493570 |
Synonyms:
(-)-Riboflavin
1-Deoxy-1-(3,4-dihydro-7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10(2H)-yl)-D-ribitol
1-Deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol
6,7-Dimethyl-9-D-ribitylisoalloxazine
6,7-Dimethyl-9-ribitylisoalloxazine
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4(3H,10H)-dione
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)-benzo[g]pteridine-2,4(3H,10H)-dione
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)isoalloxazine
7,8-DIMETHYL-10-[(2S,3S,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-2H,3H,4H,10H-BENZO[G]PTERIDINE-2,4-DIONE
7,8-Dimethyl-10-ribitylisoalloxazine
Beflavin
Beflavine
Benzo[g]pteridine riboflavin deriv.
Bisulase
e 101
e101
E-B2
Flavaxin
Flavin BB
Flaxain
FOOD Yellow 15
FREEDA
Hyre
INS NO. 101(I)
Lactobene
|
Lactoflavin
Lactoflavine
NCI-0033298
NSC-33298
Ribipca
Ribocrisina
Riboderm
Riboflavin
RIBOFLAVIN (VIT B2)
RIBOFLAVIN TETRABUTYRATE
Riboflavina
RIBOFLAVINE
Riboflavinum
Ribosyn
Ribotone
Ribovel
Russupteridine yellow III
San yellow b
Vitaflavine
Vitamin b 2
Vitamin b2
Vitamin Bi
Vitamin g
Vitasan b2
|
|
33 |
|
Folate |
|
|
|
|
|
34 |
|
Vitamins |
|
|
|
|
|
35 |
|
Vitamin B9 |
|
|
|
|
|
36 |
|
Trace Elements |
|
|
|
|
|
37 |
|
Photosensitizing Agents |
|
|
|
|
|
38 |
|
Vitamin B2 |
|
|
|
|
|
Synonyms:
|
39 |
|
Vitamin B Complex |
|
|
|
|
|
40 |
|
Dermatologic Agents |
|
|
|
|
|
41 |
|
Micronutrients |
|
|
|
|
|
42 |
|
Anti-Inflammatory Agents |
|
|
|
|
|
43 |
|
Analgesics, Opioid |
|
|
|
|
|
44 |
|
Liver Extracts |
|
|
|
|
|
45 |
|
Immunoglobulins |
|
|
|
|
|
46 |
|
Antibodies |
|
|
|
|
|
47 |
|
Hemostatics |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 58)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome |
Completed |
NCT00190411 |
Phase 4 |
celiprolol;Control |
2 |
Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers |
Recruiting |
NCT05603741 |
Phase 4 |
0.9% Sodium Chloride Injection;Lidocaine Injection 2% |
3 |
Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled Study |
Recruiting |
NCT04890431 |
Phase 4 |
Oxygen;Placebo |
4 |
Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial. |
Completed |
NCT02597361 |
Phase 3 |
Irbesartan;Placebo |
5 |
A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome |
Recruiting |
NCT05432466 |
Phase 3 |
ACER-002 (celiprolol) 200 mg BID;Placebo BID |
6 |
The Use of Ultrasound-Guided Dextrose Prolotherapy in Low Back Pain in Patients With Hypermobile-Type, Ehlers-Danlos Syndrome |
Not yet recruiting |
NCT05279937 |
Phase 3 |
Dextrose 50% Intravenous Solution;Lidocaine 1% Injectable Solution |
7 |
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE) |
Suspended |
NCT05463679 |
Phase 3 |
Enzastaurin;Placebo |
8 |
A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome |
Completed |
NCT00001966 |
Phase 2 |
Mind-body therapy |
9 |
Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial |
Recruiting |
NCT04977388 |
Phase 1, Phase 2 |
Droxidopa |
10 |
Oxytocin Treatment for Chronic Pain in Hypermobile Ehlers-Danlos Syndrome |
Enrolling by invitation |
NCT05405257 |
Phase 1, Phase 2 |
Oxytocin |
11 |
Compression Garments Effects on Postural Balance of Patients With Hypermobility Type of Ehlers-danlos Syndrome, a Prospective Study on 40 Patients |
Unknown status |
NCT03359135 |
|
|
12 |
Effectiveness of Wearing a Compression Garment (SED CICATREX® Model) for Patients With Hypermobility Type of Ehlers-Danlos Syndrome |
Unknown status |
NCT02144532 |
|
|
13 |
Study of Arterial Properties by Ultra-high Frequency Ultrasound in Fibromuscular Dysplasia and Vascular Ehlers-Danlos Syndrome |
Unknown status |
NCT03596437 |
|
|
14 |
Gait Retraining in Patients With Joint Hypermobility Syndrome/Hypermobile Ehlers Danlos Syndrome |
Unknown status |
NCT03575182 |
|
|
15 |
Validity of Somatosensori Remediation for Postural Control in the Treatment of Ehlers-Danlos Syndrome Hypermobility Type (hEDS) |
Unknown status |
NCT04020107 |
|
|
16 |
Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI |
Unknown status |
NCT01307527 |
|
Riboflavin |
17 |
Origins and Impact of EDS in Connective Tissues and Skin |
Unknown status |
NCT02721797 |
|
|
18 |
Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos Syndrome |
Completed |
NCT02712060 |
|
|
19 |
Effects of a Multidisciplinary Outpatient Rehabilitation Program on Physical Capacity and Quality of Life in Patients With Ehlers-Danlos Syndrome. |
Completed |
NCT04680793 |
|
|
20 |
Evaluation of an Education Program for Patients With Hypermobility Type Ehlers-Danlos Syndrome |
Completed |
NCT02817490 |
|
|
21 |
Obstructive Sleep Apnoea in Ehlers-Danlos Syndrome |
Completed |
NCT02435745 |
|
|
22 |
Evaluation of a Cohort of Patients With Ehlers-Danlos Syndrome Treated With Orthopedic Surgery (SED-eval) |
Completed |
NCT05137379 |
|
|
23 |
Identification of Plasmatic Biomarkers in Vascular Ehlers-Danlos Syndrome |
Completed |
NCT02165085 |
|
|
24 |
Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia ("POTS" -- Postural Orthostatic Tachycardia Syndrome)Later in Life -- a Retrospective Analysis |
Completed |
NCT01367977 |
|
|
25 |
Lung Volume Perception and Impact of a Cognitive Task on Ventilation in Healthy Subjects and Subjects With Hypermobile Ehlers-Danlos Syndrome. |
Completed |
NCT05000151 |
|
|
26 |
A Retrospective, Observational, Multicenter, Study to Collect Clinical Safety and Performance Data of POLYTHESE® Vascular Prostheses |
Completed |
NCT05516043 |
|
|
27 |
Integrative Medicine for Hypermobility Spectrum Disorder (HSD) and Ehlers-Danlos (EDS) Syndromes: A Mixed-methods Feasibility Study |
Completed |
NCT04734041 |
|
|
28 |
Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan |
Completed |
NCT02985710 |
|
|
29 |
Opioid-Free Intravenous Anesthesia for Patients With Joint Hypermobility Syndrome Undergoing Craneo-Cervical Fixation: A Case-series Study Focused on Anti-hyperalgesic Approach |
Completed |
NCT04437589 |
|
|
30 |
Establishment of Local Arterial Stiffness Normal Values (Carotid and Femoral) on Healthy Volunteers Using Supersonic Shear Imaging |
Completed |
NCT01096264 |
|
|
31 |
Clinical and Molecular Manifestations of Heritable Disorders of Connective Tissue |
Completed |
NCT00270686 |
|
|
32 |
Clinical and Molecular Manifestations of Heritable Connective Tissue Disorders |
Completed |
NCT00001641 |
|
|
33 |
Standing Cognition and Co-morbidities of POTS Evaluation |
Completed |
NCT03602482 |
|
|
34 |
Vascular Fundus Changes in Patients With High Probability of CCSVI (Chronic Cerebrospinal Venous Insufficiency) |
Completed |
NCT01356134 |
|
|
35 |
IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients |
Completed |
NCT01446783 |
|
mecasermin;Saline |
36 |
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions |
Completed |
NCT01322165 |
|
|
37 |
Impact Study on Cerecare Compression Garments in the Treatment of Ehlers-Danlos Syndromes |
Completed |
NCT03451188 |
|
|
38 |
Measuring Central Sensitization and Physical Activity in Adolescents With Hypermobility Spectrum Disorder or Hypermobile Ehlers-Danlos Syndrome |
Recruiting |
NCT05633225 |
|
|
39 |
Investigation of Light Exposure on Pain Severity and Quality of Life in Individuals With Hypermobile Ehlers-Danlos Syndrome: A Pilot Study |
Recruiting |
NCT05561270 |
|
|
40 |
Registry of Ehlers-Danlos Syndrome That Collects Clinical, Functional, Genetic, Genealogical, Imaging, Surgical, Quality of Life Data. Data Are Linked to Patients Biological Sample |
Recruiting |
NCT04133272 |
|
|
41 |
Comprehensive Assessment of Nutrition & Dietary Intervention in Hypermobile Ehlers Danlos Syndrome (hEDS/HSD): a Personalised Approach: Phase 2 & 3 |
Recruiting |
NCT05148039 |
|
|
42 |
Hypermobile Ehlers-Danlos Syndrome: Efficacy of Non-invasive Vagal Nerve Stimulation and Effects on Brain-Gut Physiology |
Recruiting |
NCT05212129 |
|
|
43 |
Evaluation of the Effect of Custom Compression Garments on Standing Static Balance in Ehlers Danlos Syndrome |
Recruiting |
NCT03986229 |
|
|
44 |
Evaluation and Management of Dyspnea in Hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD) |
Recruiting |
NCT04972565 |
|
|
45 |
Retuning the Nervous System in Youth With Chronic Pain |
Recruiting |
NCT03686748 |
Early Phase 1 |
|
46 |
Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices |
Recruiting |
NCT02050113 |
|
|
47 |
Autonomic Neuropathy and Its Pathophysiology in Autoimmune Autonomic Neuropathies, Postural Orthostatic Tachycardia Syndrome and Ehlers Danlos Syndromes: Peripheral Autonomic Small Fiber Neuropathy or Central Autonomic Failure? |
Recruiting |
NCT04310644 |
|
|
48 |
Pathogenetic Basis of Aortopathy and Aortic Valve Disease |
Recruiting |
NCT03440697 |
|
|
49 |
Face Study of the Effects of Needling Using the Straberi Epistamp for the Improvement of Fine Lines and Skin Laxity. |
Recruiting |
NCT04742803 |
|
|
50 |
Determine the Causative Genetic Variations in Patients With Ehlers-Danlos Syndrome |
Active, not recruiting |
NCT03093493 |
|
|
|